ClinicalTrials.gg
WithdrawnNCT06979492ProTIPUpdated Oct 19, 2026

Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease

A Phase 4 interventional study of Prophylactic Transfusion Intervention group: Transfusion and Control group in Sickle Cell Disease and Pregnancy Related, sponsored by Emory University. Withdrawn at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Emory University · Phase 4, Interventional, and Prevention

How we know

Why this study was withdrawn
The study was withdrawn due to no enrollment
Updated Oct 19, 2026Now WithdrawnStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Anemia, Sickle Cell by Emory University — 4 open to participants now, 6 under way, none of them phase 3. Anemia, Sickle Cell · Emory University.

Enrollment
24th of 25
0 · median 24
Started
2026
with 1 other
Phase 4
Only one
of the 29
Registered
27th of 29
by date

Among the 29 studies in Anemia, Sickle Cell by Emory University, this one is the 24th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2026, is the only one in phase 4, and was the 27th registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

4 of the 29 studies in Anemia, Sickle Cell by Emory University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Anemia, Sickle Cell by Emory University, or all of them as a file.
02

Study summary

The goal of this study is to determine if there is a positive effect of prophylactic red blood cell (RBC) transfusion of leukoreduced, ABO, Rh (D/Cc/Ee) and Kell matched blood compared to standard of care on the number of episodes of acute sickle cell disease (SCD) manifestations or pregnancy-related complications requiring acute health care encounters (acute care/ER/Hospital visits) or resulting in death over the entirety of pregnancy until 2 months post-partum in women with SCD.

RBC transfusion is the only disease-modifying therapy for pregnant women with SCD, and it is considered a standard treatment option however, there exists no consensus on the role of transfusion therapy in preventing SCD-related pregnancy complications.

Participants will be randomly assigned to repeated red blood cell transfusions or the standard of care. Participants will be on study for about 8-10 months (Pregnancy through 2 months post-partum).

Read the detailed description

Sickle cell disease (SCD) is a common genetic disorder that results from the homozygous presence of abnormal β-globin chains (hemoglobin Hb SS, Hb SC, HbSβ thalassemia). SCD causes red blood cells to become rigid, leading to various acute and chronic manifestations: chronic hemolytic anemia, poor growth, acute vaso-occlusive pain crises (VOC), priapism (in men) acute ischemic stroke, acute chest syndrome (ACS), and chronic organ damage within the spleen, kidneys, liver, lungs and heart.

High rates of both maternal and fetal morbidity and mortality complicate pregnancy in patients affected by SCD. SCD pregnancies have been linked to higher rates of obstetrical complications, including preeclampsia, venous thromboembolism, intrauterine growth restriction, preterm delivery, and small-for-gestational-age infants. In addition, sickle-related maternal complications are common during pregnancy. More than 50% of women with SCD have a VOC in the antenatal period (76% for HbSS vs 27% for Hb SC). ACS in pregnancy is seen in 7% to 20% of women with HbSS and approximately 5% in women with HbSC. Prophylactic transfusion therapy has established benefits in stroke prevention and preoperative optimization in SCD patients, but its use in pregnancy has not been established. Because hydroxyurea (HU) may be teratogenic, RBC transfusion is the only disease-modifying therapy available for pregnant women with SCD.

The decision to put a pregnant woman with SCD on chronic transfusion therapy is entirely based on provider preference and patient willingness. RBC transfusions are considered a standard treatment option for pregnant women with SCD and transfusion therapy widely used, however there exists no consensus among providers on the role of chronic transfusion therapy in preventing SCD-related pregnancy complications and no prospective randomized controlled study investigating the role of prophylactic transfusion for prevention of both maternal and fetal morbidity has been done.

03

Conditions studied

  • Sickle Cell Disease
  • Pregnancy Related

Keywords

  • Blood transfusion
  • Anemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female
  • Diagnosis of SCD of any genotype (i.e., HbSS, HbSC, HbSβ thalassemia)
  • 18 Years and older
  • Currently pregnant at 6 weeks through 20 weeks of gestation.
  • Ability to understand the purposes and risks of the study and willingly give .
  • For participants with private health insurance, insurance pre-approval for blood transfusions

Exclusion criteria

Exclusion Criteria:

  • Currently on chronic transfusion therapy before pregnancy
  • Prior history of DHTR with hyperhemolysis
  • Red cell antibody history, which would prevent the provision of adequate red cell units to support chronic transfusions.
  • Unable or unwilling to receive blood transfusion for social, religious, or clinical reasons
  • Known current triplet pregnancy
  • Current diagnosis of major medical or psychiatric comorbidity, which in the randomizing clinician's opinion renders them unable to enter a clinical trial.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Other
    Standard of Care

    Patients randomized to the control group will receive standard care for SCD alone. As part of the standard of care, women with SCD who become pregnant and who are on hydroxyurea (HU) will have the HU suspended by their primary SCD provider.

    Other: Control group

  • Experimental
    Red Blood Cell (RBC) Transfusion

    Participants will receive a blood transfusion between 6 and 20 weeks of gestation. It will be repeated at 3-6 week intervals, aiming to maintain HbS \<30%

    Biological: Prophylactic Transfusion Intervention group: Transfusion

  • No intervention
    Normal health controls

    Research testing on discarded, deidentified samples (placentas) of up to 10 women whose placentas were deemed normal, healthy, and full term by a clinical pathologist.

Interventions

  • BiologicalProphylactic Transfusion Intervention group: Transfusion

    For participants randomized to the prophylactic transfusion intervention group, the first RBC transfusion will occur within 3 weeks of randomization. All transfusions will be managed per SOC. SOC prophylactic RBC transfusion management is as follows: transfusions are performed at 3-6 week intervals with the intent to maintain a pre-transfusion hemoglobin S level at \<30%. All participants will have a complete blood count, reticulocyte count, hemoglobin fractionation, complete metabolic profile with LDH, ferritin, and type/screen at baseline and within 3 days of all monthly transfusions. All RBC transfusions must be compatible between the recipient and the donor and antigen matched for Rh (D/Cc/Ee) and Kell antigens at a minimum. For participants with a previous history of RBC alloimmunization, extended matched RBCs will be provided (Rh, Kell, Duffy, Kidd, S/s) per NHLBI/ASH guidelines to minimize further alloimmunization.

  • OtherControl group

    Participants randomized to the control group will be followed per SOC. SOC management for pregnant women with SCD includes but is not limited to * Clinic appointments with an SCD provider every 2 months * Lab draws - complete blood count, reticulocyte count, hemoglobin fractionation, complete metabolic profile with LDH and ferritin.

06

What researchers measure

Primary outcomes

  1. Hospital admissions rate

    Number of participants who require hospital admission during study participation divided by the total number of participants. Collected from medical records

    Time frame: Baseline (enrollment) up to 8 weeks post-partum

  2. Number of maternal emergency department (ED)/Acute care visits

    Collected from medical records

    Time frame: Baseline (enrollment) up to 8 weeks post-partum

  3. Number of SCD-related complications per group

    Sickle cell complications (vaso-occlusive crisis (VOC) / acute chest syndrome (ACS) / cerebral stroke) collected from medical records

    Time frame: Baseline (enrollment) up to 8 weeks post-partum

  4. Number of participants with pregnancy related complications

    Number of participants who will develop pregnancy-related complications (pre-eclampsia, venous thromboembolism, infection). Collected from medical records

    Time frame: Baseline (enrollment) up to 8 weeks post-partum

  5. Maternal death

    Number of women who die at any gestational age during pregnancy or within 8 weeks after delivery from any cause arising from the pregnancy or its management, but not from incidental or accidental causes, divided by the total number of participants.

    Time frame: From randomization up to 8 weeks post-partum

Secondary outcomes

  1. Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me)

    The Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me) is a validated patient-reported outcome measure of physical, mental, and social health in adults with SCD. Patient-reported outcome measure of pain level in the past 7 days. The ASCQ-Me pain scale ranges from 0-100, with a standardized sickle cell disease population mean of 50 (standard deviation=10), where lower scores signify worse disease impact. A modified version of the validated ASCQ-Me will be used.

    Time frame: 2, 4, 6, 8 and 10 months post randomization.

  2. Patient reported outcomes measurement information system (PROMIS)

    The patient-reported outcomes will be assessed using a health-related quality of life questionnaire, a modified version of the validated sickle-cell specific quality of life instruments, PROMIS The PROMIS Short-Form scale is a generic measure of health-related quality of life (HRQL) that assesses physical, mental, and social health. It has a recall period of 7 days and yields separate Physical Health and Mental Health subscale scores, which range from 0 to 100 and are standardized to a US population mean of 50 and standard deviation (SD) of 10. Each question usually has five response options ranging in value from one to five. To find the total raw score for a short form with all questions answered, sum up the values of the responses to each question. For example, for the adult 8-item form, the lowest possible raw score is 8; the highest possible raw score is 40. For each subscale, a higher score connotes better functioning.

    Time frame: 2, 4, 6, 8 and 10 months post randomization.

  3. Infant birth weight

    Infant's birth weight from medical records.

    Time frame: At delivery up to 42 weeks of pregnancy

  4. Preterm delivery

    Number of women delivered before 37 weeks gestational age divided by the total number of participants randomized.

    Time frame: Up to delivery (36 weeks of pregnancy)

  5. APGAR Scores

    The Apgar score is a scoring system doctors and nurses use to assess newborns after delivery. At most, a child will receive an overall score of 10. A score of 7 to 10 five minutes after birth is reassuring, 4 to 7 is moderately abnormal, and 0 to 3 is concerning. The Apgar scoring system is divided into five categories. Each category receives a score of 0 to 2 points. A: Activity/muscle tone P: Pulse/heart rate G: Grimace (response to stimulation, such as suctioning the baby's nose) A: Appearance (color) R: Respiration/breathing

    Time frame: 1 and 5 minutes after neonate's delivery

  6. Number of neonatal intensive care unit/critical care admissions

    The neonate's admission to the intensive care unit/critical care admission will be documented from medical records.

    Time frame: After neonate's delivery up to 1 week post-partum

  7. Perinatal death

    Number of babies who died from 28 weeks gestational age up to seven days post-delivery (comprising all still births and early neonatal deaths divided by total births.

    Time frame: From 28 weeks of pregnancy up to 1 week post-partum

  8. Fetal demise/stillbirth

    Fetal demise refers to the spontaneous intrauterine death of a fetus at any time during pregnancy.

    Time frame: From enrollment up to 42 weeks of pregnancy

  9. Number of participants with new RBC alloantibodies

    Participants who have been assigned to receive chronic simple blood transfusions will have monthly labs prior to their scheduled transfusion as per SOC to assess for new alloantibodies.

    Time frame: From enrollment up to 8 weeks post-partum

  10. Number of participants with transfusion reactions

    Participants will be carefully monitored for transfusion-related adverse events throughout the intervention phase of the study.

    Time frame: From enrollment up to 8 weeks post-partum

  11. Number of participants with an increase in iron overload (serum ferritin)

    Transfusion iron burden will be monitored with monthly serum ferritin levels during the study, which is standard of care monitoring for patients undergoing chronic transfusion therapy.

    Time frame: From enrollment up to 8 weeks post-partum

  12. Number of participants with placental pathology

    Per standard of care women with sickle cell disease routinely have their placentas sent to pathology for analysis. Once the routine testing is done placentas will undergo additional histopathological and biochemical analysis for research purposes.

    Time frame: Up to 5 days post-delivery

07

Study locations

1 site
  • Grady Health System
    Atlanta, Georgia 30303, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Sep 2026; primary completion for May 2028, 20 months later.

Start moved once since we started tracking on Sep 25, 2026: Apr 2026 → Sep 2026, on Oct 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2025
First posted
May 20, 2025
StartEst.
Sep 2026was Apr 2026
Primary completionEst.
May 2028
CompletionEst.
May 2028
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Withdrawn The study was withdrawn due to no enrollment
changed Oct 19, 2026
Start date
Apr 2026→Sep 2026
Oct 19, 2026
Enrollment
50 (estimated)→0 (actual)
Oct 19, 2026
Interventions
Arms added: Normal health controls
Oct 19, 2026
Secondary outcomes
1 added
What changed in the outcomes
  • AddedNumber of participants with placental pathologyTime frame: Up to 5 days post-delivery
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Recruiting→Withdrawn
    Why stopped The study was withdrawn due to no enrollment
    Start date Apr 2026→Sep 2026
    Enrollment 50 (estimated)→0 (actual)
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedNumber of participants with placental pathologyTime frame: Up to 5 days post-delivery
    Interventions Arms added: Normal health controls
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06979492
Lead sponsor
Emory University
Responsible party
Ross Fasano (Associate Professor, Emory University) — Principal investigator
First posted
May 20, 2025
Start date
Sep 2026 (estimated)
Primary completion
May 2028 (estimated)
Completion
May 2028 (estimated)
Last update
Oct 19, 2026

Study contacts

Ross Fasano, MD
principal investigator · Emory University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion